nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—urinary bladder cancer—kidney cancer	0.105	0.233	CtDrD
Methotrexate—bone cancer—kidney cancer	0.1	0.224	CtDrD
Methotrexate—muscle cancer—kidney cancer	0.0886	0.198	CtDrD
Methotrexate—testicular cancer—kidney cancer	0.0831	0.185	CtDrD
Methotrexate—lung cancer—kidney cancer	0.0715	0.16	CtDrD
Methotrexate—ABCB1—kidney cancer	0.0383	1	CbGaD
Methotrexate—TYMS—Capecitabine—kidney cancer	0.0375	0.12	CbGbCtD
Methotrexate—TYMS—Gemcitabine—kidney cancer	0.026	0.083	CbGbCtD
Methotrexate—ABCC10—Gemcitabine—kidney cancer	0.0215	0.0684	CbGbCtD
Methotrexate—ABCC10—Paclitaxel—kidney cancer	0.0194	0.0618	CbGbCtD
Methotrexate—ABCC10—Vincristine—kidney cancer	0.0167	0.0533	CbGbCtD
Methotrexate—SLCO1B3—Paclitaxel—kidney cancer	0.0108	0.0345	CbGbCtD
Methotrexate—ABCC3—Vincristine—kidney cancer	0.0105	0.0335	CbGbCtD
Methotrexate—ABCC1—Dactinomycin—kidney cancer	0.0105	0.0334	CbGbCtD
Methotrexate—ABCC10—Doxorubicin—kidney cancer	0.0104	0.0333	CbGbCtD
Methotrexate—SLCO1B1—Pazopanib—kidney cancer	0.00965	0.0308	CbGbCtD
Methotrexate—ABCC4—Sorafenib—kidney cancer	0.00827	0.0264	CbGbCtD
Methotrexate—ABCG2—Pazopanib—kidney cancer	0.00767	0.0245	CbGbCtD
Methotrexate—ABCC1—Paclitaxel—kidney cancer	0.00749	0.0239	CbGbCtD
Methotrexate—ABCG2—Dactinomycin—kidney cancer	0.00701	0.0224	CbGbCtD
Methotrexate—ABCC4—Sunitinib—kidney cancer	0.0067	0.0214	CbGbCtD
Methotrexate—ABCC3—Doxorubicin—kidney cancer	0.00657	0.021	CbGbCtD
Methotrexate—ABCC1—Vinblastine—kidney cancer	0.00657	0.0209	CbGbCtD
Methotrexate—ABCC1—Vincristine—kidney cancer	0.00645	0.0206	CbGbCtD
Methotrexate—ABCC2—Paclitaxel—kidney cancer	0.00554	0.0177	CbGbCtD
Methotrexate—ABCG2—Erlotinib—kidney cancer	0.00547	0.0174	CbGbCtD
Methotrexate—ABCB1—Temsirolimus—kidney cancer	0.00526	0.0168	CbGbCtD
Methotrexate—ABCG2—Paclitaxel—kidney cancer	0.00501	0.016	CbGbCtD
Methotrexate—ABCC2—Sorafenib—kidney cancer	0.00492	0.0157	CbGbCtD
Methotrexate—ABCC2—Vinblastine—kidney cancer	0.00486	0.0155	CbGbCtD
Methotrexate—ABCC2—Vincristine—kidney cancer	0.00478	0.0152	CbGbCtD
Methotrexate—FOLR1—nephron—kidney cancer	0.00448	0.11	CbGeAlD
Methotrexate—ABCG2—Sorafenib—kidney cancer	0.00445	0.0142	CbGbCtD
Methotrexate—ABCG2—Vincristine—kidney cancer	0.00432	0.0138	CbGbCtD
Methotrexate—ABCC1—Doxorubicin—kidney cancer	0.00403	0.0129	CbGbCtD
Methotrexate—ABCC2—Sunitinib—kidney cancer	0.00399	0.0127	CbGbCtD
Methotrexate—ALB—Erlotinib—kidney cancer	0.00377	0.012	CbGbCtD
Methotrexate—ABCG2—Sunitinib—kidney cancer	0.0036	0.0115	CbGbCtD
Methotrexate—ABCC2—Doxorubicin—kidney cancer	0.00299	0.00952	CbGbCtD
Methotrexate—ABCB1—Pazopanib—kidney cancer	0.00277	0.00882	CbGbCtD
Methotrexate—ABCG2—Doxorubicin—kidney cancer	0.0027	0.00861	CbGbCtD
Methotrexate—ABCB1—Dactinomycin—kidney cancer	0.00253	0.00806	CbGbCtD
Methotrexate—ABCB1—Gemcitabine—kidney cancer	0.002	0.00637	CbGbCtD
Methotrexate—ABCB1—Erlotinib—kidney cancer	0.00197	0.00629	CbGbCtD
Methotrexate—SLCO3A1—nephron—kidney cancer	0.00185	0.0454	CbGeAlD
Methotrexate—ABCB1—Paclitaxel—kidney cancer	0.00181	0.00576	CbGbCtD
Methotrexate—ABCB1—Sorafenib—kidney cancer	0.0016	0.00512	CbGbCtD
Methotrexate—ABCB1—Vinblastine—kidney cancer	0.00158	0.00505	CbGbCtD
Methotrexate—ABCB1—Vincristine—kidney cancer	0.00156	0.00497	CbGbCtD
Methotrexate—ABCB1—Sunitinib—kidney cancer	0.0013	0.00414	CbGbCtD
Methotrexate—SLC22A8—nephron—kidney cancer	0.00115	0.0283	CbGeAlD
Methotrexate—ABCB1—Doxorubicin—kidney cancer	0.000973	0.0031	CbGbCtD
Methotrexate—FOLR1—nephron tubule—kidney cancer	0.000967	0.0237	CbGeAlD
Methotrexate—SLC22A8—urine—kidney cancer	0.000924	0.0227	CbGeAlD
Methotrexate—FOLR1—renal system—kidney cancer	0.000879	0.0216	CbGeAlD
Methotrexate—FOLR1—kidney—kidney cancer	0.00085	0.0208	CbGeAlD
Methotrexate—FOLR1—cortex of kidney—kidney cancer	0.000827	0.0203	CbGeAlD
Methotrexate—ABCC11—gonad—kidney cancer	0.000756	0.0185	CbGeAlD
Methotrexate—SLC19A1—gonad—kidney cancer	0.000691	0.017	CbGeAlD
Methotrexate—GGH—nephron tubule—kidney cancer	0.000642	0.0158	CbGeAlD
Methotrexate—GGH—renal system—kidney cancer	0.000584	0.0143	CbGeAlD
Methotrexate—SLCO4C1—nephron tubule—kidney cancer	0.00057	0.014	CbGeAlD
Methotrexate—GGH—kidney—kidney cancer	0.000565	0.0139	CbGeAlD
Methotrexate—GGH—cortex of kidney—kidney cancer	0.00055	0.0135	CbGeAlD
Methotrexate—ATIC—Everolimus—Temsirolimus—kidney cancer	0.000537	0.295	CbGdCrCtD
Methotrexate—GGH—gonad—kidney cancer	0.000524	0.0128	CbGeAlD
Methotrexate—SLCO4C1—renal system—kidney cancer	0.000518	0.0127	CbGeAlD
Methotrexate—SLCO4C1—kidney—kidney cancer	0.000501	0.0123	CbGeAlD
Methotrexate—ATIC—renal system—kidney cancer	0.000497	0.0122	CbGeAlD
Methotrexate—SLCO4C1—cortex of kidney—kidney cancer	0.000488	0.012	CbGeAlD
Methotrexate—FPGS—cortex of kidney—kidney cancer	0.000483	0.0119	CbGeAlD
Methotrexate—ATIC—kidney—kidney cancer	0.00048	0.0118	CbGeAlD
Methotrexate—FPGS—cardiac atrium—kidney cancer	0.00046	0.0113	CbGeAlD
Methotrexate—FPGS—Everolimus—Temsirolimus—kidney cancer	0.000457	0.251	CbGdCrCtD
Methotrexate—ATIC—gonad—kidney cancer	0.000445	0.0109	CbGeAlD
Methotrexate—SLC22A11—nephron tubule—kidney cancer	0.000441	0.0108	CbGeAlD
Methotrexate—SLC22A6—nephron tubule—kidney cancer	0.000416	0.0102	CbGeAlD
Methotrexate—SLCO1C1—renal system—kidney cancer	0.000413	0.0101	CbGeAlD
Methotrexate—SLC22A11—renal system—kidney cancer	0.000401	0.00984	CbGeAlD
Methotrexate—SLCO1C1—kidney—kidney cancer	0.000399	0.00979	CbGeAlD
Methotrexate—SLC22A7—renal system—kidney cancer	0.000391	0.0096	CbGeAlD
Methotrexate—SLC22A11—kidney—kidney cancer	0.000388	0.00951	CbGeAlD
Methotrexate—SLC22A7—kidney—kidney cancer	0.000378	0.00928	CbGeAlD
Methotrexate—SLC22A11—cortex of kidney—kidney cancer	0.000378	0.00926	CbGeAlD
Methotrexate—TYMS—nephron tubule—kidney cancer	0.00037	0.00909	CbGeAlD
Methotrexate—SLC22A7—cortex of kidney—kidney cancer	0.000368	0.00904	CbGeAlD
Methotrexate—DHFR—nephron tubule—kidney cancer	0.000367	0.009	CbGeAlD
Methotrexate—SLCO3A1—renal system—kidney cancer	0.000363	0.00891	CbGeAlD
Methotrexate—SLC22A6—cortex of kidney—kidney cancer	0.000356	0.00873	CbGeAlD
Methotrexate—PGD—nephron tubule—kidney cancer	0.000353	0.00865	CbGeAlD
Methotrexate—SLCO3A1—kidney—kidney cancer	0.000351	0.00861	CbGeAlD
Methotrexate—SLCO3A1—cortex of kidney—kidney cancer	0.000342	0.00839	CbGeAlD
Methotrexate—DHFR—renal system—kidney cancer	0.000333	0.00818	CbGeAlD
Methotrexate—SLCO3A1—gonad—kidney cancer	0.000326	0.00799	CbGeAlD
Methotrexate—SLCO3A1—cardiac atrium—kidney cancer	0.000325	0.00798	CbGeAlD
Methotrexate—DHFR—kidney—kidney cancer	0.000322	0.00791	CbGeAlD
Methotrexate—PGD—renal system—kidney cancer	0.000321	0.00786	CbGeAlD
Methotrexate—TYMS—cortex of kidney—kidney cancer	0.000317	0.00778	CbGeAlD
Methotrexate—DHFR—cortex of kidney—kidney cancer	0.000314	0.0077	CbGeAlD
Methotrexate—AOX1—nephron tubule—kidney cancer	0.000311	0.00762	CbGeAlD
Methotrexate—PGD—kidney—kidney cancer	0.00031	0.0076	CbGeAlD
Methotrexate—TYMS—gonad—kidney cancer	0.000302	0.00741	CbGeAlD
Methotrexate—PGD—cortex of kidney—kidney cancer	0.000302	0.0074	CbGeAlD
Methotrexate—SLC16A1—renal system—kidney cancer	0.000299	0.00734	CbGeAlD
Methotrexate—DHFR—gonad—kidney cancer	0.000299	0.00734	CbGeAlD
Methotrexate—DHFR—cardiac atrium—kidney cancer	0.000299	0.00733	CbGeAlD
Methotrexate—SLCO1B1—renal system—kidney cancer	0.000291	0.00714	CbGeAlD
Methotrexate—SLC16A1—kidney—kidney cancer	0.000289	0.0071	CbGeAlD
Methotrexate—PGD—gonad—kidney cancer	0.000287	0.00705	CbGeAlD
Methotrexate—PGD—cardiac atrium—kidney cancer	0.000287	0.00704	CbGeAlD
Methotrexate—AOX1—renal system—kidney cancer	0.000282	0.00693	CbGeAlD
Methotrexate—SLCO1B1—kidney—kidney cancer	0.000281	0.0069	CbGeAlD
Methotrexate—ABCC3—renal system—kidney cancer	0.000276	0.00678	CbGeAlD
Methotrexate—ABCC10—renal system—kidney cancer	0.000275	0.00674	CbGeAlD
Methotrexate—AOX1—kidney—kidney cancer	0.000273	0.0067	CbGeAlD
Methotrexate—SLC16A1—gonad—kidney cancer	0.000268	0.00658	CbGeAlD
Methotrexate—SLC16A1—cardiac atrium—kidney cancer	0.000268	0.00658	CbGeAlD
Methotrexate—ABCC3—kidney—kidney cancer	0.000267	0.00655	CbGeAlD
Methotrexate—AOX1—cortex of kidney—kidney cancer	0.000266	0.00652	CbGeAlD
Methotrexate—ABCC10—kidney—kidney cancer	0.000266	0.00652	CbGeAlD
Methotrexate—ABCC10—cortex of kidney—kidney cancer	0.000259	0.00635	CbGeAlD
Methotrexate—AOX1—gonad—kidney cancer	0.000253	0.00621	CbGeAlD
Methotrexate—AOX1—cardiac atrium—kidney cancer	0.000253	0.0062	CbGeAlD
Methotrexate—ABCC4—nephron tubule—kidney cancer	0.000251	0.00615	CbGeAlD
Methotrexate—SLC22A8—nephron tubule—kidney cancer	0.000249	0.0061	CbGeAlD
Methotrexate—ABCC10—gonad—kidney cancer	0.000246	0.00605	CbGeAlD
Methotrexate—ABCC10—cardiac atrium—kidney cancer	0.000246	0.00604	CbGeAlD
Methotrexate—ABCC2—nephron tubule—kidney cancer	0.000243	0.00596	CbGeAlD
Methotrexate—SLCO1A2—renal system—kidney cancer	0.000237	0.00581	CbGeAlD
Methotrexate—SLCO1A2—kidney—kidney cancer	0.000229	0.00562	CbGeAlD
Methotrexate—ABCC4—renal system—kidney cancer	0.000228	0.00559	CbGeAlD
Methotrexate—SLC22A8—renal system—kidney cancer	0.000226	0.00555	CbGeAlD
Methotrexate—TYMS—Docetaxel—Paclitaxel—kidney cancer	0.000224	0.123	CbGdCrCtD
Methotrexate—ABCC2—renal system—kidney cancer	0.000221	0.00541	CbGeAlD
Methotrexate—ABCC4—kidney—kidney cancer	0.00022	0.00541	CbGeAlD
Methotrexate—SLC22A8—kidney—kidney cancer	0.000219	0.00536	CbGeAlD
Methotrexate—ABCC4—cortex of kidney—kidney cancer	0.000215	0.00527	CbGeAlD
Methotrexate—ABCC2—kidney—kidney cancer	0.000213	0.00523	CbGeAlD
Methotrexate—SLC22A8—cortex of kidney—kidney cancer	0.000213	0.00523	CbGeAlD
Methotrexate—ABCC2—cortex of kidney—kidney cancer	0.000208	0.0051	CbGeAlD
Methotrexate—ABCC1—cortex of kidney—kidney cancer	0.000183	0.00449	CbGeAlD
Methotrexate—ABCG2—nephron tubule—kidney cancer	0.000177	0.00434	CbGeAlD
Methotrexate—ABCC1—cardiac atrium—kidney cancer	0.000174	0.00427	CbGeAlD
Methotrexate—TYMS—Sirolimus—Everolimus—kidney cancer	0.000107	0.0589	CbGdCrCtD
Methotrexate—TYMS—Sirolimus—Temsirolimus—kidney cancer	0.000107	0.0589	CbGdCrCtD
Methotrexate—TYMS—Gefitinib—Erlotinib—kidney cancer	0.000107	0.0588	CbGdCrCtD
Methotrexate—ABCB1—nephron tubule—kidney cancer	8.73e-05	0.00214	CbGeAlD
Methotrexate—ABCB1—renal system—kidney cancer	7.94e-05	0.00195	CbGeAlD
Methotrexate—ABCB1—kidney—kidney cancer	7.67e-05	0.00188	CbGeAlD
Methotrexate—ABCB1—cortex of kidney—kidney cancer	7.47e-05	0.00183	CbGeAlD
Methotrexate—TYMS—Vinorelbine—Vinblastine—kidney cancer	7.17e-05	0.0394	CbGdCrCtD
Methotrexate—TYMS—Vinorelbine—Vincristine—kidney cancer	7.17e-05	0.0394	CbGdCrCtD
Methotrexate—ABCB1—gonad—kidney cancer	7.12e-05	0.00175	CbGeAlD
Methotrexate—TYMS—Vincristine—Vinblastine—kidney cancer	6.13e-05	0.0337	CbGdCrCtD
Methotrexate—TYMS—Vinblastine—Vincristine—kidney cancer	4.93e-05	0.0271	CbGdCrCtD
Methotrexate—TYMS—Azacitidine—Gemcitabine—kidney cancer	2.89e-05	0.0159	CbGdCrCtD
Methotrexate—Insomnia—Gemcitabine—kidney cancer	2.48e-05	0.000229	CcSEcCtD
Methotrexate—Eye disorder—Capecitabine—kidney cancer	2.48e-05	0.000229	CcSEcCtD
Methotrexate—Headache—Erlotinib—kidney cancer	2.47e-05	0.000228	CcSEcCtD
Methotrexate—Tinnitus—Capecitabine—kidney cancer	2.47e-05	0.000228	CcSEcCtD
Methotrexate—Pain—Vincristine—kidney cancer	2.47e-05	0.000228	CcSEcCtD
Methotrexate—Osteoarthritis—Doxorubicin—kidney cancer	2.47e-05	0.000228	CcSEcCtD
Methotrexate—Paraesthesia—Gemcitabine—kidney cancer	2.46e-05	0.000227	CcSEcCtD
Methotrexate—Cardiac disorder—Capecitabine—kidney cancer	2.46e-05	0.000227	CcSEcCtD
Methotrexate—Cough—Paclitaxel—kidney cancer	2.45e-05	0.000226	CcSEcCtD
Methotrexate—Asthenia—Sunitinib—kidney cancer	2.45e-05	0.000226	CcSEcCtD
Methotrexate—Dyspnoea—Gemcitabine—kidney cancer	2.44e-05	0.000226	CcSEcCtD
Methotrexate—Nausea—Vinblastine—kidney cancer	2.44e-05	0.000225	CcSEcCtD
Methotrexate—Somnolence—Gemcitabine—kidney cancer	2.44e-05	0.000225	CcSEcCtD
Methotrexate—Convulsion—Paclitaxel—kidney cancer	2.44e-05	0.000225	CcSEcCtD
Methotrexate—Nausea—Everolimus—kidney cancer	2.43e-05	0.000224	CcSEcCtD
Methotrexate—Diarrhoea—Sorafenib—kidney cancer	2.43e-05	0.000224	CcSEcCtD
Methotrexate—Pruritus—Sunitinib—kidney cancer	2.42e-05	0.000223	CcSEcCtD
Methotrexate—Angiopathy—Capecitabine—kidney cancer	2.41e-05	0.000222	CcSEcCtD
Methotrexate—Immune system disorder—Capecitabine—kidney cancer	2.39e-05	0.000221	CcSEcCtD
Methotrexate—Myalgia—Paclitaxel—kidney cancer	2.39e-05	0.000221	CcSEcCtD
Methotrexate—Arthralgia—Paclitaxel—kidney cancer	2.39e-05	0.000221	CcSEcCtD
Methotrexate—Chest pain—Paclitaxel—kidney cancer	2.39e-05	0.000221	CcSEcCtD
Methotrexate—Mediastinal disorder—Capecitabine—kidney cancer	2.39e-05	0.00022	CcSEcCtD
Methotrexate—Decreased appetite—Gemcitabine—kidney cancer	2.38e-05	0.00022	CcSEcCtD
Methotrexate—Hypersensitivity—Dactinomycin—kidney cancer	2.38e-05	0.00022	CcSEcCtD
Methotrexate—Chills—Capecitabine—kidney cancer	2.38e-05	0.00022	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	2.38e-05	0.000219	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Gemcitabine—kidney cancer	2.37e-05	0.000218	CcSEcCtD
Methotrexate—Discomfort—Paclitaxel—kidney cancer	2.37e-05	0.000218	CcSEcCtD
Methotrexate—Fatigue—Gemcitabine—kidney cancer	2.36e-05	0.000218	CcSEcCtD
Methotrexate—Gastrointestinal pain—Vincristine—kidney cancer	2.36e-05	0.000218	CcSEcCtD
Methotrexate—Dizziness—Sorafenib—kidney cancer	2.35e-05	0.000217	CcSEcCtD
Methotrexate—Pain—Gemcitabine—kidney cancer	2.34e-05	0.000216	CcSEcCtD
Methotrexate—Nausea—Erlotinib—kidney cancer	2.34e-05	0.000216	CcSEcCtD
Methotrexate—Alopecia—Capecitabine—kidney cancer	2.34e-05	0.000216	CcSEcCtD
Methotrexate—Mood swings—Doxorubicin—kidney cancer	2.34e-05	0.000216	CcSEcCtD
Methotrexate—Diarrhoea—Sunitinib—kidney cancer	2.34e-05	0.000216	CcSEcCtD
Methotrexate—Ataxia—Doxorubicin—kidney cancer	2.32e-05	0.000214	CcSEcCtD
Methotrexate—Mental disorder—Capecitabine—kidney cancer	2.32e-05	0.000214	CcSEcCtD
Methotrexate—Asthenia—Dactinomycin—kidney cancer	2.32e-05	0.000214	CcSEcCtD
Methotrexate—Confusional state—Paclitaxel—kidney cancer	2.31e-05	0.000214	CcSEcCtD
Methotrexate—Erythema—Capecitabine—kidney cancer	2.31e-05	0.000213	CcSEcCtD
Methotrexate—Malnutrition—Capecitabine—kidney cancer	2.31e-05	0.000213	CcSEcCtD
Methotrexate—Anaphylactic shock—Paclitaxel—kidney cancer	2.29e-05	0.000212	CcSEcCtD
Methotrexate—Body temperature increased—Vincristine—kidney cancer	2.28e-05	0.000211	CcSEcCtD
Methotrexate—Abdominal pain—Vincristine—kidney cancer	2.28e-05	0.000211	CcSEcCtD
Methotrexate—Liver function test abnormal—Doxorubicin—kidney cancer	2.28e-05	0.00021	CcSEcCtD
Methotrexate—Infection—Paclitaxel—kidney cancer	2.28e-05	0.00021	CcSEcCtD
Methotrexate—Dysgeusia—Capecitabine—kidney cancer	2.26e-05	0.000209	CcSEcCtD
Methotrexate—Dizziness—Sunitinib—kidney cancer	2.26e-05	0.000208	CcSEcCtD
Methotrexate—Feeling abnormal—Gemcitabine—kidney cancer	2.26e-05	0.000208	CcSEcCtD
Methotrexate—Vomiting—Sorafenib—kidney cancer	2.26e-05	0.000208	CcSEcCtD
Methotrexate—Nervous system disorder—Paclitaxel—kidney cancer	2.25e-05	0.000208	CcSEcCtD
Methotrexate—Thrombocytopenia—Paclitaxel—kidney cancer	2.25e-05	0.000207	CcSEcCtD
Methotrexate—Rash—Sorafenib—kidney cancer	2.24e-05	0.000207	CcSEcCtD
Methotrexate—Dermatitis—Sorafenib—kidney cancer	2.24e-05	0.000206	CcSEcCtD
Methotrexate—Back pain—Capecitabine—kidney cancer	2.23e-05	0.000206	CcSEcCtD
Methotrexate—Breast disorder—Doxorubicin—kidney cancer	2.23e-05	0.000206	CcSEcCtD
Methotrexate—Skin disorder—Paclitaxel—kidney cancer	2.23e-05	0.000206	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	2.22e-05	0.000205	CcSEcCtD
Methotrexate—Headache—Sorafenib—kidney cancer	2.22e-05	0.000205	CcSEcCtD
Methotrexate—Hyperhidrosis—Paclitaxel—kidney cancer	2.22e-05	0.000205	CcSEcCtD
Methotrexate—Diarrhoea—Dactinomycin—kidney cancer	2.21e-05	0.000204	CcSEcCtD
Methotrexate—Anorexia—Paclitaxel—kidney cancer	2.19e-05	0.000202	CcSEcCtD
Methotrexate—Vision blurred—Capecitabine—kidney cancer	2.17e-05	0.000201	CcSEcCtD
Methotrexate—Vomiting—Sunitinib—kidney cancer	2.17e-05	0.0002	CcSEcCtD
Methotrexate—Body temperature increased—Gemcitabine—kidney cancer	2.17e-05	0.0002	CcSEcCtD
Methotrexate—Rash—Sunitinib—kidney cancer	2.15e-05	0.000199	CcSEcCtD
Methotrexate—Dermatitis—Sunitinib—kidney cancer	2.15e-05	0.000199	CcSEcCtD
Methotrexate—Hypotension—Paclitaxel—kidney cancer	2.14e-05	0.000198	CcSEcCtD
Methotrexate—Ill-defined disorder—Capecitabine—kidney cancer	2.14e-05	0.000198	CcSEcCtD
Methotrexate—Headache—Sunitinib—kidney cancer	2.14e-05	0.000198	CcSEcCtD
Methotrexate—Asthma—Doxorubicin—kidney cancer	2.13e-05	0.000197	CcSEcCtD
Methotrexate—Anaemia—Capecitabine—kidney cancer	2.13e-05	0.000197	CcSEcCtD
Methotrexate—Hypersensitivity—Vincristine—kidney cancer	2.13e-05	0.000196	CcSEcCtD
Methotrexate—Eosinophilia—Doxorubicin—kidney cancer	2.11e-05	0.000195	CcSEcCtD
Methotrexate—Nausea—Sorafenib—kidney cancer	2.11e-05	0.000195	CcSEcCtD
Methotrexate—Pancreatitis—Doxorubicin—kidney cancer	2.09e-05	0.000193	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Paclitaxel—kidney cancer	2.09e-05	0.000193	CcSEcCtD
Methotrexate—Malaise—Capecitabine—kidney cancer	2.08e-05	0.000192	CcSEcCtD
Methotrexate—Insomnia—Paclitaxel—kidney cancer	2.08e-05	0.000192	CcSEcCtD
Methotrexate—Vertigo—Capecitabine—kidney cancer	2.07e-05	0.000191	CcSEcCtD
Methotrexate—Asthenia—Vincristine—kidney cancer	2.07e-05	0.000191	CcSEcCtD
Methotrexate—Leukopenia—Capecitabine—kidney cancer	2.07e-05	0.000191	CcSEcCtD
Methotrexate—Paraesthesia—Paclitaxel—kidney cancer	2.06e-05	0.00019	CcSEcCtD
Methotrexate—Vomiting—Dactinomycin—kidney cancer	2.06e-05	0.00019	CcSEcCtD
Methotrexate—Dyspnoea—Paclitaxel—kidney cancer	2.05e-05	0.000189	CcSEcCtD
Methotrexate—Somnolence—Paclitaxel—kidney cancer	2.04e-05	0.000188	CcSEcCtD
Methotrexate—Rash—Dactinomycin—kidney cancer	2.04e-05	0.000188	CcSEcCtD
Methotrexate—Nausea—Sunitinib—kidney cancer	2.03e-05	0.000187	CcSEcCtD
Methotrexate—Pancytopenia—Doxorubicin—kidney cancer	2.03e-05	0.000187	CcSEcCtD
Methotrexate—Dyspepsia—Paclitaxel—kidney cancer	2.02e-05	0.000186	CcSEcCtD
Methotrexate—Cough—Capecitabine—kidney cancer	2.01e-05	0.000186	CcSEcCtD
Methotrexate—Neutropenia—Doxorubicin—kidney cancer	2e-05	0.000184	CcSEcCtD
Methotrexate—Dysuria—Doxorubicin—kidney cancer	2e-05	0.000184	CcSEcCtD
Methotrexate—Decreased appetite—Paclitaxel—kidney cancer	2e-05	0.000184	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Doxorubicin—kidney cancer	1.98e-05	0.000183	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Paclitaxel—kidney cancer	1.98e-05	0.000183	CcSEcCtD
Methotrexate—Fatigue—Paclitaxel—kidney cancer	1.98e-05	0.000183	CcSEcCtD
Methotrexate—Diarrhoea—Vincristine—kidney cancer	1.98e-05	0.000182	CcSEcCtD
Methotrexate—Asthenia—Gemcitabine—kidney cancer	1.97e-05	0.000182	CcSEcCtD
Methotrexate—Arthralgia—Capecitabine—kidney cancer	1.96e-05	0.000181	CcSEcCtD
Methotrexate—Chest pain—Capecitabine—kidney cancer	1.96e-05	0.000181	CcSEcCtD
Methotrexate—Myalgia—Capecitabine—kidney cancer	1.96e-05	0.000181	CcSEcCtD
Methotrexate—Pain—Paclitaxel—kidney cancer	1.96e-05	0.000181	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	1.95e-05	0.00018	CcSEcCtD
Methotrexate—Photosensitivity reaction—Doxorubicin—kidney cancer	1.95e-05	0.00018	CcSEcCtD
Methotrexate—Discomfort—Capecitabine—kidney cancer	1.94e-05	0.000179	CcSEcCtD
Methotrexate—Pruritus—Gemcitabine—kidney cancer	1.94e-05	0.000179	CcSEcCtD
Methotrexate—Nausea—Dactinomycin—kidney cancer	1.92e-05	0.000177	CcSEcCtD
Methotrexate—Pneumonia—Doxorubicin—kidney cancer	1.91e-05	0.000177	CcSEcCtD
Methotrexate—Dizziness—Vincristine—kidney cancer	1.91e-05	0.000176	CcSEcCtD
Methotrexate—Drowsiness—Doxorubicin—kidney cancer	1.9e-05	0.000176	CcSEcCtD
Methotrexate—Infestation—Doxorubicin—kidney cancer	1.9e-05	0.000176	CcSEcCtD
Methotrexate—Infestation NOS—Doxorubicin—kidney cancer	1.9e-05	0.000176	CcSEcCtD
Methotrexate—Confusional state—Capecitabine—kidney cancer	1.9e-05	0.000175	CcSEcCtD
Methotrexate—Feeling abnormal—Paclitaxel—kidney cancer	1.89e-05	0.000175	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	1.89e-05	0.000174	CcSEcCtD
Methotrexate—Gastrointestinal pain—Paclitaxel—kidney cancer	1.88e-05	0.000173	CcSEcCtD
Methotrexate—Diarrhoea—Gemcitabine—kidney cancer	1.88e-05	0.000173	CcSEcCtD
Methotrexate—Renal failure—Doxorubicin—kidney cancer	1.87e-05	0.000173	CcSEcCtD
Methotrexate—Infection—Capecitabine—kidney cancer	1.87e-05	0.000173	CcSEcCtD
Methotrexate—Stomatitis—Doxorubicin—kidney cancer	1.86e-05	0.000171	CcSEcCtD
Methotrexate—Conjunctivitis—Doxorubicin—kidney cancer	1.85e-05	0.000171	CcSEcCtD
Methotrexate—Nervous system disorder—Capecitabine—kidney cancer	1.85e-05	0.00017	CcSEcCtD
Methotrexate—Thrombocytopenia—Capecitabine—kidney cancer	1.84e-05	0.00017	CcSEcCtD
Methotrexate—Vomiting—Vincristine—kidney cancer	1.84e-05	0.00017	CcSEcCtD
Methotrexate—Skin disorder—Capecitabine—kidney cancer	1.83e-05	0.000169	CcSEcCtD
Methotrexate—Sweating—Doxorubicin—kidney cancer	1.82e-05	0.000168	CcSEcCtD
Methotrexate—Urticaria—Paclitaxel—kidney cancer	1.82e-05	0.000168	CcSEcCtD
Methotrexate—Rash—Vincristine—kidney cancer	1.82e-05	0.000168	CcSEcCtD
Methotrexate—Hyperhidrosis—Capecitabine—kidney cancer	1.82e-05	0.000168	CcSEcCtD
Methotrexate—Dermatitis—Vincristine—kidney cancer	1.82e-05	0.000168	CcSEcCtD
Methotrexate—Haematuria—Doxorubicin—kidney cancer	1.81e-05	0.000168	CcSEcCtD
Methotrexate—Body temperature increased—Paclitaxel—kidney cancer	1.81e-05	0.000167	CcSEcCtD
Methotrexate—Abdominal pain—Paclitaxel—kidney cancer	1.81e-05	0.000167	CcSEcCtD
Methotrexate—Headache—Vincristine—kidney cancer	1.81e-05	0.000167	CcSEcCtD
Methotrexate—Hepatobiliary disease—Doxorubicin—kidney cancer	1.8e-05	0.000166	CcSEcCtD
Methotrexate—Epistaxis—Doxorubicin—kidney cancer	1.8e-05	0.000166	CcSEcCtD
Methotrexate—Anorexia—Capecitabine—kidney cancer	1.8e-05	0.000166	CcSEcCtD
Methotrexate—Agranulocytosis—Doxorubicin—kidney cancer	1.78e-05	0.000164	CcSEcCtD
Methotrexate—Hypotension—Capecitabine—kidney cancer	1.76e-05	0.000162	CcSEcCtD
Methotrexate—Vomiting—Gemcitabine—kidney cancer	1.74e-05	0.000161	CcSEcCtD
Methotrexate—Rash—Gemcitabine—kidney cancer	1.73e-05	0.00016	CcSEcCtD
Methotrexate—Dermatitis—Gemcitabine—kidney cancer	1.73e-05	0.000159	CcSEcCtD
Methotrexate—Haemoglobin—Doxorubicin—kidney cancer	1.72e-05	0.000159	CcSEcCtD
Methotrexate—Headache—Gemcitabine—kidney cancer	1.72e-05	0.000158	CcSEcCtD
Methotrexate—Nausea—Vincristine—kidney cancer	1.72e-05	0.000158	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Capecitabine—kidney cancer	1.72e-05	0.000158	CcSEcCtD
Methotrexate—Haemorrhage—Doxorubicin—kidney cancer	1.71e-05	0.000158	CcSEcCtD
Methotrexate—Hepatitis—Doxorubicin—kidney cancer	1.71e-05	0.000158	CcSEcCtD
Methotrexate—Insomnia—Capecitabine—kidney cancer	1.7e-05	0.000157	CcSEcCtD
Methotrexate—Pharyngitis—Doxorubicin—kidney cancer	1.7e-05	0.000157	CcSEcCtD
Methotrexate—Paraesthesia—Capecitabine—kidney cancer	1.69e-05	0.000156	CcSEcCtD
Methotrexate—Hypersensitivity—Paclitaxel—kidney cancer	1.69e-05	0.000156	CcSEcCtD
Methotrexate—Urinary tract disorder—Doxorubicin—kidney cancer	1.69e-05	0.000156	CcSEcCtD
Methotrexate—Dyspnoea—Capecitabine—kidney cancer	1.68e-05	0.000155	CcSEcCtD
Methotrexate—Urethral disorder—Doxorubicin—kidney cancer	1.68e-05	0.000155	CcSEcCtD
Methotrexate—Dyspepsia—Capecitabine—kidney cancer	1.66e-05	0.000153	CcSEcCtD
Methotrexate—Visual impairment—Doxorubicin—kidney cancer	1.65e-05	0.000152	CcSEcCtD
Methotrexate—Asthenia—Paclitaxel—kidney cancer	1.65e-05	0.000152	CcSEcCtD
Methotrexate—Decreased appetite—Capecitabine—kidney cancer	1.64e-05	0.000151	CcSEcCtD
Methotrexate—Nausea—Gemcitabine—kidney cancer	1.63e-05	0.00015	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Capecitabine—kidney cancer	1.63e-05	0.00015	CcSEcCtD
Methotrexate—Fatigue—Capecitabine—kidney cancer	1.62e-05	0.00015	CcSEcCtD
Methotrexate—Pruritus—Paclitaxel—kidney cancer	1.62e-05	0.00015	CcSEcCtD
Methotrexate—Erythema multiforme—Doxorubicin—kidney cancer	1.62e-05	0.000149	CcSEcCtD
Methotrexate—Pain—Capecitabine—kidney cancer	1.61e-05	0.000149	CcSEcCtD
Methotrexate—Eye disorder—Doxorubicin—kidney cancer	1.6e-05	0.000147	CcSEcCtD
Methotrexate—Tinnitus—Doxorubicin—kidney cancer	1.59e-05	0.000147	CcSEcCtD
Methotrexate—Cardiac disorder—Doxorubicin—kidney cancer	1.59e-05	0.000146	CcSEcCtD
Methotrexate—Diarrhoea—Paclitaxel—kidney cancer	1.57e-05	0.000145	CcSEcCtD
Methotrexate—Feeling abnormal—Capecitabine—kidney cancer	1.55e-05	0.000143	CcSEcCtD
Methotrexate—Angiopathy—Doxorubicin—kidney cancer	1.55e-05	0.000143	CcSEcCtD
Methotrexate—Immune system disorder—Doxorubicin—kidney cancer	1.54e-05	0.000142	CcSEcCtD
Methotrexate—Gastrointestinal pain—Capecitabine—kidney cancer	1.54e-05	0.000142	CcSEcCtD
Methotrexate—Mediastinal disorder—Doxorubicin—kidney cancer	1.54e-05	0.000142	CcSEcCtD
Methotrexate—Chills—Doxorubicin—kidney cancer	1.53e-05	0.000142	CcSEcCtD
Methotrexate—Dizziness—Paclitaxel—kidney cancer	1.52e-05	0.00014	CcSEcCtD
Methotrexate—Alopecia—Doxorubicin—kidney cancer	1.51e-05	0.000139	CcSEcCtD
Methotrexate—Mental disorder—Doxorubicin—kidney cancer	1.5e-05	0.000138	CcSEcCtD
Methotrexate—Urticaria—Capecitabine—kidney cancer	1.5e-05	0.000138	CcSEcCtD
Methotrexate—Body temperature increased—Capecitabine—kidney cancer	1.49e-05	0.000137	CcSEcCtD
Methotrexate—Abdominal pain—Capecitabine—kidney cancer	1.49e-05	0.000137	CcSEcCtD
Methotrexate—Malnutrition—Doxorubicin—kidney cancer	1.49e-05	0.000137	CcSEcCtD
Methotrexate—Erythema—Doxorubicin—kidney cancer	1.49e-05	0.000137	CcSEcCtD
Methotrexate—Vomiting—Paclitaxel—kidney cancer	1.46e-05	0.000135	CcSEcCtD
Methotrexate—Dysgeusia—Doxorubicin—kidney cancer	1.46e-05	0.000134	CcSEcCtD
Methotrexate—Rash—Paclitaxel—kidney cancer	1.45e-05	0.000134	CcSEcCtD
Methotrexate—Dermatitis—Paclitaxel—kidney cancer	1.45e-05	0.000133	CcSEcCtD
Methotrexate—Back pain—Doxorubicin—kidney cancer	1.44e-05	0.000133	CcSEcCtD
Methotrexate—Headache—Paclitaxel—kidney cancer	1.44e-05	0.000133	CcSEcCtD
Methotrexate—Vision blurred—Doxorubicin—kidney cancer	1.4e-05	0.000129	CcSEcCtD
Methotrexate—Hypersensitivity—Capecitabine—kidney cancer	1.39e-05	0.000128	CcSEcCtD
Methotrexate—Ill-defined disorder—Doxorubicin—kidney cancer	1.38e-05	0.000127	CcSEcCtD
Methotrexate—Anaemia—Doxorubicin—kidney cancer	1.37e-05	0.000127	CcSEcCtD
Methotrexate—Nausea—Paclitaxel—kidney cancer	1.36e-05	0.000126	CcSEcCtD
Methotrexate—Asthenia—Capecitabine—kidney cancer	1.35e-05	0.000125	CcSEcCtD
Methotrexate—Malaise—Doxorubicin—kidney cancer	1.34e-05	0.000124	CcSEcCtD
Methotrexate—Vertigo—Doxorubicin—kidney cancer	1.34e-05	0.000123	CcSEcCtD
Methotrexate—Pruritus—Capecitabine—kidney cancer	1.33e-05	0.000123	CcSEcCtD
Methotrexate—Leukopenia—Doxorubicin—kidney cancer	1.33e-05	0.000123	CcSEcCtD
Methotrexate—Cough—Doxorubicin—kidney cancer	1.3e-05	0.00012	CcSEcCtD
Methotrexate—Convulsion—Doxorubicin—kidney cancer	1.29e-05	0.000119	CcSEcCtD
Methotrexate—Diarrhoea—Capecitabine—kidney cancer	1.29e-05	0.000119	CcSEcCtD
Methotrexate—Arthralgia—Doxorubicin—kidney cancer	1.27e-05	0.000117	CcSEcCtD
Methotrexate—Chest pain—Doxorubicin—kidney cancer	1.27e-05	0.000117	CcSEcCtD
Methotrexate—Myalgia—Doxorubicin—kidney cancer	1.27e-05	0.000117	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	1.26e-05	0.000116	CcSEcCtD
Methotrexate—Discomfort—Doxorubicin—kidney cancer	1.25e-05	0.000115	CcSEcCtD
Methotrexate—Dizziness—Capecitabine—kidney cancer	1.25e-05	0.000115	CcSEcCtD
Methotrexate—Confusional state—Doxorubicin—kidney cancer	1.22e-05	0.000113	CcSEcCtD
Methotrexate—Anaphylactic shock—Doxorubicin—kidney cancer	1.21e-05	0.000112	CcSEcCtD
Methotrexate—Infection—Doxorubicin—kidney cancer	1.21e-05	0.000111	CcSEcCtD
Methotrexate—Vomiting—Capecitabine—kidney cancer	1.2e-05	0.000111	CcSEcCtD
Methotrexate—Nervous system disorder—Doxorubicin—kidney cancer	1.19e-05	0.00011	CcSEcCtD
Methotrexate—Thrombocytopenia—Doxorubicin—kidney cancer	1.19e-05	0.00011	CcSEcCtD
Methotrexate—Rash—Capecitabine—kidney cancer	1.19e-05	0.00011	CcSEcCtD
Methotrexate—Dermatitis—Capecitabine—kidney cancer	1.19e-05	0.000109	CcSEcCtD
Methotrexate—Headache—Capecitabine—kidney cancer	1.18e-05	0.000109	CcSEcCtD
Methotrexate—Skin disorder—Doxorubicin—kidney cancer	1.18e-05	0.000109	CcSEcCtD
Methotrexate—Hyperhidrosis—Doxorubicin—kidney cancer	1.17e-05	0.000108	CcSEcCtD
Methotrexate—Anorexia—Doxorubicin—kidney cancer	1.16e-05	0.000107	CcSEcCtD
Methotrexate—Hypotension—Doxorubicin—kidney cancer	1.13e-05	0.000105	CcSEcCtD
Methotrexate—Nausea—Capecitabine—kidney cancer	1.12e-05	0.000103	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Doxorubicin—kidney cancer	1.11e-05	0.000102	CcSEcCtD
Methotrexate—Insomnia—Doxorubicin—kidney cancer	1.1e-05	0.000101	CcSEcCtD
Methotrexate—Paraesthesia—Doxorubicin—kidney cancer	1.09e-05	0.000101	CcSEcCtD
Methotrexate—Dyspnoea—Doxorubicin—kidney cancer	1.08e-05	9.99e-05	CcSEcCtD
Methotrexate—Somnolence—Doxorubicin—kidney cancer	1.08e-05	9.96e-05	CcSEcCtD
Methotrexate—Dyspepsia—Doxorubicin—kidney cancer	1.07e-05	9.86e-05	CcSEcCtD
Methotrexate—Decreased appetite—Doxorubicin—kidney cancer	1.06e-05	9.74e-05	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Doxorubicin—kidney cancer	1.05e-05	9.67e-05	CcSEcCtD
Methotrexate—Fatigue—Doxorubicin—kidney cancer	1.05e-05	9.66e-05	CcSEcCtD
Methotrexate—Pain—Doxorubicin—kidney cancer	1.04e-05	9.58e-05	CcSEcCtD
Methotrexate—Feeling abnormal—Doxorubicin—kidney cancer	1e-05	9.23e-05	CcSEcCtD
Methotrexate—Gastrointestinal pain—Doxorubicin—kidney cancer	9.93e-06	9.16e-05	CcSEcCtD
Methotrexate—Urticaria—Doxorubicin—kidney cancer	9.64e-06	8.9e-05	CcSEcCtD
Methotrexate—Abdominal pain—Doxorubicin—kidney cancer	9.6e-06	8.86e-05	CcSEcCtD
Methotrexate—Body temperature increased—Doxorubicin—kidney cancer	9.6e-06	8.86e-05	CcSEcCtD
Methotrexate—Hypersensitivity—Doxorubicin—kidney cancer	8.94e-06	8.25e-05	CcSEcCtD
Methotrexate—Asthenia—Doxorubicin—kidney cancer	8.71e-06	8.04e-05	CcSEcCtD
Methotrexate—Pruritus—Doxorubicin—kidney cancer	8.59e-06	7.93e-05	CcSEcCtD
Methotrexate—Diarrhoea—Doxorubicin—kidney cancer	8.31e-06	7.67e-05	CcSEcCtD
Methotrexate—Dizziness—Doxorubicin—kidney cancer	8.03e-06	7.41e-05	CcSEcCtD
Methotrexate—Vomiting—Doxorubicin—kidney cancer	7.72e-06	7.12e-05	CcSEcCtD
Methotrexate—Rash—Doxorubicin—kidney cancer	7.65e-06	7.06e-05	CcSEcCtD
Methotrexate—Dermatitis—Doxorubicin—kidney cancer	7.65e-06	7.06e-05	CcSEcCtD
Methotrexate—Headache—Doxorubicin—kidney cancer	7.61e-06	7.02e-05	CcSEcCtD
Methotrexate—Nausea—Doxorubicin—kidney cancer	7.21e-06	6.66e-05	CcSEcCtD
Methotrexate—ALB—Metabolism—PGK1—kidney cancer	3.96e-06	8.03e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SLC5A3—kidney cancer	3.96e-06	8.03e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—GSTP1—kidney cancer	3.95e-06	8.02e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—RAF1—kidney cancer	3.94e-06	7.99e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Transmembrane transport of small molecules—RAF1—kidney cancer	3.94e-06	7.99e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GSTT1—kidney cancer	3.93e-06	7.98e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ACHE—kidney cancer	3.93e-06	7.98e-05	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—TP53—kidney cancer	3.93e-06	7.97e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—PIK3CA—kidney cancer	3.92e-06	7.95e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—POMC—kidney cancer	3.91e-06	7.93e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	3.91e-06	7.93e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PSMD7—kidney cancer	3.9e-06	7.92e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—ERBB2—kidney cancer	3.9e-06	7.91e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—BCHE—kidney cancer	3.89e-06	7.9e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CA2—kidney cancer	3.89e-06	7.9e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	3.89e-06	7.89e-05	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—PIK3CA—kidney cancer	3.89e-06	7.88e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—LDHB—kidney cancer	3.88e-06	7.88e-05	CbGpPWpGaD
Methotrexate—PGD—Disease—KRAS—kidney cancer	3.87e-06	7.85e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—IL2—kidney cancer	3.86e-06	7.84e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—RAF1—kidney cancer	3.85e-06	7.81e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MTOR—kidney cancer	3.85e-06	7.8e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—SLC5A5—kidney cancer	3.85e-06	7.8e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CD4—kidney cancer	3.84e-06	7.79e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—CYP1A1—kidney cancer	3.82e-06	7.75e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PTGS2—kidney cancer	3.81e-06	7.73e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—ERBB2—kidney cancer	3.81e-06	7.72e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ALAD—kidney cancer	3.79e-06	7.7e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—TP53—kidney cancer	3.79e-06	7.69e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	3.77e-06	7.66e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—MTOR—kidney cancer	3.76e-06	7.62e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—CD4—kidney cancer	3.75e-06	7.61e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ABCB1—kidney cancer	3.74e-06	7.59e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—VEGFA—kidney cancer	3.74e-06	7.59e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—SCARB1—kidney cancer	3.72e-06	7.55e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—PTGS2—kidney cancer	3.72e-06	7.55e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—SLC2A1—kidney cancer	3.71e-06	7.54e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	3.71e-06	7.53e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ST3GAL2—kidney cancer	3.7e-06	7.51e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	3.7e-06	7.51e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—BCHE—kidney cancer	3.7e-06	7.51e-05	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—RAF1—kidney cancer	3.7e-06	7.51e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTGS1—kidney cancer	3.69e-06	7.48e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	3.67e-06	7.45e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—SLC5A5—kidney cancer	3.65e-06	7.42e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—GSTM1—kidney cancer	3.63e-06	7.37e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ALDH1A1—kidney cancer	3.62e-06	7.34e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PSMD7—kidney cancer	3.61e-06	7.33e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CDKN1B—kidney cancer	3.61e-06	7.32e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	3.6e-06	7.31e-05	CbGpPWpGaD
Methotrexate—ABCC2—Transmembrane transport of small molecules—RAF1—kidney cancer	3.58e-06	7.27e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CDKN2B—kidney cancer	3.58e-06	7.27e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	3.58e-06	7.27e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—POMC—kidney cancer	3.56e-06	7.21e-05	CbGpPWpGaD
Methotrexate—PGD—Disease—PIK3CA—kidney cancer	3.55e-06	7.21e-05	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—RAF1—kidney cancer	3.54e-06	7.19e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—MAPK3—kidney cancer	3.54e-06	7.18e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—SLC2A1—kidney cancer	3.53e-06	7.16e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—CDKN1B—kidney cancer	3.53e-06	7.15e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—RAF1—kidney cancer	3.5e-06	7.1e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.49e-06	7.09e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SLC5A3—kidney cancer	3.47e-06	7.04e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PGK1—kidney cancer	3.47e-06	7.04e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—ERBB2—kidney cancer	3.46e-06	7.03e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CYP1A1—kidney cancer	3.44e-06	6.99e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—GSTP1—kidney cancer	3.44e-06	6.99e-05	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—TP53—kidney cancer	3.43e-06	6.96e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—BCHE—kidney cancer	3.43e-06	6.95e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	3.42e-06	6.95e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—MTOR—kidney cancer	3.42e-06	6.93e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—CD4—kidney cancer	3.41e-06	6.92e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CTNNB1—kidney cancer	3.41e-06	6.92e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—LDHB—kidney cancer	3.4e-06	6.9e-05	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—ABCB1—kidney cancer	3.4e-06	6.9e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—PTGS2—kidney cancer	3.39e-06	6.87e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—SLC5A5—kidney cancer	3.38e-06	6.87e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—MAPK1—kidney cancer	3.37e-06	6.83e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CA9—kidney cancer	3.37e-06	6.83e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—RAF1—kidney cancer	3.37e-06	6.83e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—CTNNB1—kidney cancer	3.33e-06	6.76e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PTEN—kidney cancer	3.32e-06	6.74e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	3.29e-06	6.68e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—VEGFA—kidney cancer	3.28e-06	6.66e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—SLC2A1—kidney cancer	3.27e-06	6.63e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ABCB1—kidney cancer	3.26e-06	6.61e-05	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—PIK3CA—kidney cancer	3.25e-06	6.6e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—PTEN—kidney cancer	3.25e-06	6.59e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—POMC—kidney cancer	3.24e-06	6.57e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	3.23e-06	6.56e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—CDKN1B—kidney cancer	3.21e-06	6.51e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PTGS2—kidney cancer	3.19e-06	6.48e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—KRAS—kidney cancer	3.18e-06	6.45e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—GSTM1—kidney cancer	3.16e-06	6.42e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.14e-06	6.38e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.14e-06	6.36e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PTGS2—kidney cancer	3.12e-06	6.33e-05	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—RAF1—kidney cancer	3.12e-06	6.32e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—MAPK3—kidney cancer	3.11e-06	6.3e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—POMC—kidney cancer	3.1e-06	6.3e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GSTP1—kidney cancer	3.1e-06	6.29e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	3.06e-06	6.21e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—CTNNB1—kidney cancer	3.03e-06	6.15e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CYP1A1—kidney cancer	3e-06	6.09e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.99e-06	6.06e-05	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PIK3CA—kidney cancer	2.98e-06	6.04e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	2.98e-06	6.04e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—MAPK1—kidney cancer	2.96e-06	6e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—PTEN—kidney cancer	2.95e-06	5.99e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CA9—kidney cancer	2.95e-06	5.99e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GSTP1—kidney cancer	2.94e-06	5.97e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ABCB1—kidney cancer	2.93e-06	5.95e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—PIK3CA—kidney cancer	2.92e-06	5.93e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	2.91e-06	5.91e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HIF1A—kidney cancer	2.86e-06	5.81e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CRABP1—kidney cancer	2.86e-06	5.81e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TSC2—kidney cancer	2.86e-06	5.8e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GSTM1—kidney cancer	2.85e-06	5.78e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—POMC—kidney cancer	2.85e-06	5.78e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MAPK3—kidney cancer	2.84e-06	5.76e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTGS2—kidney cancer	2.84e-06	5.75e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.83e-06	5.74e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TP53—kidney cancer	2.83e-06	5.74e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ABCB1—kidney cancer	2.79e-06	5.65e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PTEN—kidney cancer	2.78e-06	5.65e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—MAPK3—kidney cancer	2.77e-06	5.63e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MYC—kidney cancer	2.76e-06	5.6e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	2.75e-06	5.58e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GSTP1—kidney cancer	2.73e-06	5.53e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PTEN—kidney cancer	2.72e-06	5.52e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GSTM1—kidney cancer	2.71e-06	5.49e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MAPK1—kidney cancer	2.7e-06	5.48e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CYP1A1—kidney cancer	2.7e-06	5.48e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—MYC—kidney cancer	2.7e-06	5.47e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ITPR2—kidney cancer	2.66e-06	5.4e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—MAPK1—kidney cancer	2.64e-06	5.35e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTGS2—kidney cancer	2.58e-06	5.24e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ABCB1—kidney cancer	2.58e-06	5.24e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—POMC—kidney cancer	2.57e-06	5.21e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—PIK3CA—kidney cancer	2.57e-06	5.21e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CYP1A1—kidney cancer	2.56e-06	5.2e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—KRAS—kidney cancer	2.55e-06	5.18e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	2.53e-06	5.13e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—APC—kidney cancer	2.52e-06	5.12e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KIT—kidney cancer	2.52e-06	5.12e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—MAPK3—kidney cancer	2.52e-06	5.12e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CRABP1—kidney cancer	2.51e-06	5.09e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GSTM1—kidney cancer	2.5e-06	5.08e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—KRAS—kidney cancer	2.49e-06	5.06e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTGS2—kidney cancer	2.47e-06	5.02e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTEN—kidney cancer	2.47e-06	5.02e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.46e-06	5e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—MYC—kidney cancer	2.45e-06	4.98e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—POMC—kidney cancer	2.45e-06	4.98e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	2.44e-06	4.96e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTT1—kidney cancer	2.43e-06	4.92e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ACHE—kidney cancer	2.43e-06	4.92e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—MAPK1—kidney cancer	2.4e-06	4.87e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP1A1—kidney cancer	2.37e-06	4.82e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—BRAF—kidney cancer	2.37e-06	4.81e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PIK3CA—kidney cancer	2.34e-06	4.76e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ITPR2—kidney cancer	2.33e-06	4.73e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SCARB1—kidney cancer	2.3e-06	4.66e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—PIK3CA—kidney cancer	2.29e-06	4.65e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTGS1—kidney cancer	2.27e-06	4.61e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTGS2—kidney cancer	2.27e-06	4.61e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—KRAS—kidney cancer	2.27e-06	4.6e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTEN—kidney cancer	2.25e-06	4.57e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—POMC—kidney cancer	2.24e-06	4.54e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PSMD7—kidney cancer	2.23e-06	4.53e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—RAF1—kidney cancer	2.22e-06	4.51e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.22e-06	4.5e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTEN—kidney cancer	2.16e-06	4.38e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTT1—kidney cancer	2.13e-06	4.31e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ACHE—kidney cancer	2.13e-06	4.31e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—BCHE—kidney cancer	2.11e-06	4.29e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.11e-06	4.28e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SLC5A5—kidney cancer	2.09e-06	4.24e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—PIK3CA—kidney cancer	2.08e-06	4.23e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTGS2—kidney cancer	2.05e-06	4.16e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SLC2A1—kidney cancer	2.02e-06	4.09e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SCARB1—kidney cancer	2.01e-06	4.08e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—POMC—kidney cancer	2.01e-06	4.08e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTGS1—kidney cancer	1.99e-06	4.04e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IL2—kidney cancer	1.99e-06	4.04e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—RAF1—kidney cancer	1.98e-06	4.02e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTEN—kidney cancer	1.98e-06	4.02e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PIK3CA—kidney cancer	1.96e-06	3.98e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—ERBB2—kidney cancer	1.96e-06	3.98e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.96e-06	3.97e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PSMD7—kidney cancer	1.95e-06	3.96e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MTOR—kidney cancer	1.93e-06	3.92e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CD4—kidney cancer	1.93e-06	3.92e-05	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—RAF1—kidney cancer	1.92e-06	3.9e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PIK3CA—kidney cancer	1.92e-06	3.89e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTGS2—kidney cancer	1.92e-06	3.89e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—POMC—kidney cancer	1.91e-06	3.88e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—BCHE—kidney cancer	1.85e-06	3.76e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SLC5A5—kidney cancer	1.83e-06	3.71e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CDKN1B—kidney cancer	1.81e-06	3.68e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTEN—kidney cancer	1.79e-06	3.62e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTGS2—kidney cancer	1.78e-06	3.62e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—POMC—kidney cancer	1.77e-06	3.59e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SLC2A1—kidney cancer	1.77e-06	3.59e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PIK3CA—kidney cancer	1.74e-06	3.54e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CTNNB1—kidney cancer	1.71e-06	3.48e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.71e-06	3.46e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VEGFA—kidney cancer	1.69e-06	3.44e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	1.69e-06	3.42e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTP1—kidney cancer	1.68e-06	3.41e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTEN—kidney cancer	1.67e-06	3.39e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTGS2—kidney cancer	1.6e-06	3.26e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—MAPK3—kidney cancer	1.6e-06	3.25e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ABCB1—kidney cancer	1.59e-06	3.23e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CA—kidney cancer	1.59e-06	3.22e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTEN—kidney cancer	1.56e-06	3.16e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTM1—kidney cancer	1.55e-06	3.14e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTGS2—kidney cancer	1.53e-06	3.09e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—MAPK1—kidney cancer	1.52e-06	3.09e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CA—kidney cancer	1.52e-06	3.09e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTP1—kidney cancer	1.47e-06	2.99e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP1A1—kidney cancer	1.47e-06	2.97e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—KRAS—kidney cancer	1.44e-06	2.92e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MAPK3—kidney cancer	1.43e-06	2.9e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTGS2—kidney cancer	1.41e-06	2.87e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTEN—kidney cancer	1.4e-06	2.84e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CA—kidney cancer	1.4e-06	2.83e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MYC—kidney cancer	1.39e-06	2.82e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MAPK1—kidney cancer	1.36e-06	2.76e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTM1—kidney cancer	1.35e-06	2.75e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTEN—kidney cancer	1.33e-06	2.7e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CA—kidney cancer	1.32e-06	2.68e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP1A1—kidney cancer	1.28e-06	2.61e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KRAS—kidney cancer	1.28e-06	2.6e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—kidney cancer	1.28e-06	2.6e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CA—kidney cancer	1.26e-06	2.56e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTEN—kidney cancer	1.23e-06	2.5e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.2e-06	2.44e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CA—kidney cancer	1.18e-06	2.39e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CA—kidney cancer	1.1e-06	2.23e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—POMC—kidney cancer	1.09e-06	2.22e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CA—kidney cancer	9.87e-07	2e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—POMC—kidney cancer	9.57e-07	1.94e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CA—kidney cancer	9.38e-07	1.9e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTGS2—kidney cancer	8.71e-07	1.77e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CA—kidney cancer	8.69e-07	1.76e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTGS2—kidney cancer	7.63e-07	1.55e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTEN—kidney cancer	7.6e-07	1.54e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTEN—kidney cancer	6.66e-07	1.35e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CA—kidney cancer	5.36e-07	1.09e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CA—kidney cancer	4.7e-07	9.53e-06	CbGpPWpGaD
